PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 326-350 of 369

  • PI3Kα-IN-13
    Cat. No.
    A79854

    PI3Kα-IN-13

    PI3Kα-IN-13 is a selective inhibitor of PI3Kα, demonstrating an IC50 value of 2.5 nM. This compound effectively induces apoptosis in tumor cells, significantly inhibiting cancer cell proliferation across various cell lines, including MCF-7 (IC50: 0.75 μM), HCT-116 (IC50: 3.79 μM), MDA-MB-231 (IC50: 13.71 μM), and SW620 (IC50: 9.85 μM). Additionally, PI3Kα-IN-13 reduces tumor cell colony formation, migration, and invasion, making it a valuable tool for cancer research and therapeutic development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kγ inhibitor 6
    Cat. No.
    A79855

    PI3Kγ inhibitor 6

    PI3Kγ Inhibitor 6 is a selective inhibitor of the phosphoinositide 3-kinase gamma (PI3Kγ) enzyme. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory and autoimmune diseases. Its inhibition of PI3Kγ can help elucidate the signaling pathways involved in various pathological conditions, providing insights into potential therapeutic strategies.

    5 mg
    $75.00
    10 mg
    $110.00
    All 6 sizes
  • PI3Kδ-IN-17
    Cat. No.
    A79857

    PI3Kδ-IN-17

    PI3Kδ-IN-17 is a highly selective inhibitor of PI3Kδ, exhibiting an IC50 of 2.82 nM. This compound demonstrates significant anti-proliferative effects in SU-DHL-6 cells, with an IC50 value of 0.035 μM. PI3Kδ-IN-17 is valuable for research applications focusing on cancer biology and the modulation of cell proliferation pathways.

    Out of stock

    All 3 sizes
  • PX-866-17OH
    Cat. No.
    A79858

    PX-866-17OH

    PX-866-17OH is a pan-isoform inhibitor of phosphoinositide 3-kinases (PI3K) that exhibits IC50 values of 14, 57, 131, and 148 nM against PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively. Its primary action as a metabolite of PX-866 (Sonolisib) makes it a valuable tool in the study of PI3K signaling pathways. PX-866-17OH has potential applications in cancer research and therapeutic development, particularly in contexts where PI3K signaling contributes to tumor growth and survival.

    1 mg
    $185.00
    5 mg
    $575.00
    All 3 sizes
  • IMM-H012
    Cat. No.
    A79859

    IMM-H012

    IMM-H012 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), exhibiting an IC50 of 0.80 nM for PI3Kα. This compound demonstrates significant antitumor activity when used in combination with [177Lu]Lu-P4, showing synergistic effects against stomach and lung cancers. It is a valuable tool for researchers investigating PI3K signaling pathways and their implications in cancer therapeutics.

    Out of stock

    All 3 sizes
  • PI3K-IN-50
    Cat. No.
    A79861

    PI3K-IN-50

    PI3K-IN-50 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), known for its ability to interfere with key signaling pathways involved in cell growth and metabolism. This compound demonstrates potent inhibitory activity against PI3K, making it valuable for research focused on cancer, metabolic disorders, and other diseases associated with dysregulated PI3K signaling. Its utility in studying PI3K-related biological processes makes it an important tool for investigating therapeutic strategies targeting this pathway.

    Out of stock

    All 3 sizes
  • HM5023507
    Cat. No.
    A79862

    HM5023507

    HM5023507 is a selective inhibitor of PI3Kδ and PI3Kγ, exhibiting IC50 values of 4 μM and 5 μM, respectively, while showing minimal activity against PI3Kα and PI3Kβ. This compound effectively attenuates PI3Kδ/γ signaling in human basophils and suppresses the activation, function, and cytokine production of human B and T cells, impacting Th17 differentiation in CD4 T cells. In vivo studies demonstrate that HM5023507 can inhibit collagen-induced inflammatory responses in rat models, making it a valuable tool for research into inflammatory diseases, particularly rheumatoid arthritis.

    Out of stock

    All 3 sizes
  • PI3Kα-IN-11
    Cat. No.
    A79863

    PI3Kα-IN-11

    PI3Kα-IN-11 is a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα), demonstrating significant efficacy in interrupting the PI3K signaling pathway. This compound exhibits potent anticancer activity, making it a valuable tool for research on tumorigenesis and cancer therapy. Its application spans in vitro studies to evaluate the role of PI3Kα in cancer proliferation and progression, contributing to the development of targeted cancer treatments.

    1 mg
    $65.00
    5 mg
    $160.00
    All 7 sizes
  • PI3Kγ inhibitor 7
    Cat. No.
    A79864

    PI3Kγ inhibitor 7

    PI3Kγ inhibitor 7 is a selective inhibitor targeting the phosphoinositide 3-kinase gamma isoform (PI3Kγ), exhibiting an IC50 value of 3.42 nM for this target, while showing significantly higher IC50 values for PI3Kα, PI3Kβ, and PI3Kδ. This compound demonstrates notable antitumor activity, making it suitable for cancer research applications. Additionally, PI3Kγ inhibitor 7 contains an alkyne functional group, enabling its use in click chemistry reactions, specifically copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • 17β-Hydroxywortmannin
    Cat. No.
    A79865

    17β-Hydroxywortmannin

    Synonyms: Wortmannin-17β-ol

    17β-Hydroxywortmannin is a potent inhibitor of phosphatidylinositol-3-kinase (PI3K) with an impressive IC50 of 0.5 nM. This compound effectively suppresses osteoclast resorption, displaying an IC50 of 10 nM, and exhibits notable antitumor activity. It is valuable in research applications focused on cancer biology and bone metabolism.

    0.5 mg
    $105.00
    1 mg
    $190.00
    All 3 sizes
  • PI3K-IN-49
    Cat. No.
    A79867

    PI3K-IN-49

    PI3K-IN-49 is a selective phosphoinositide 3-kinase (PI3K) inhibitor. It exhibits significant antiproliferative effects in T-47D and SKBR3 cell lines, making it a valuable tool for cancer research. This compound can be utilized to investigate PI3K signaling pathways and their role in tumor growth and progression.

    Out of stock

    All 3 sizes
  • PI3Kβ-IN-1
    Cat. No.
    A79868

    PI3Kβ-IN-1

    PI3Kβ-IN-1 is a selective inhibitor of phosphoinositide 3-kinase beta (PI3Kβ) with an IC50 value of 2 nM, demonstrating potent activity against this target. This compound is suitable for in vitro and in vivo research applications aimed at investigating the role of PI3Kβ in various signaling pathways and disease models, including cancer and metabolic disorders. Its oral bioavailability enhances its potential for therapeutic development and translational studies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kγ inhibitor 5
    Cat. No.
    A79869

    PI3Kγ inhibitor 5

    PI3Kγ inhibitor 5 is a selective inhibitor of phosphoinositide 3-kinase γ (PI3Kγ), exhibiting an IC50 value of 34 nM. This compound is vital for studying the role of PI3Kγ in cellular signaling pathways, including immune response and cancer progression. It serves as a valuable tool in research focused on targeting PI3K signaling in various disease models.

    5 mg
    $795.00
    All 1 sizes
  • IHMT-PI3K-455
    Cat. No.
    A79870

    IHMT-PI3K-455

    IHMT-PI3K-455 is a selective, orally active dual inhibitor of PI3Kγ and PI3Kδ, exhibiting IC50 values of 7.1 nM and 0.57 nM for each isoform, respectively. This compound effectively suppresses AKT phosphorylation, leading to documented inhibition of tumor growth through the recruitment and activation of CD8+ cytotoxic T cells. IHMT-PI3K-455 is primarily utilized in cancer research to explore its therapeutic potential and mechanisms in tumor biology.

    Out of stock

    All 3 sizes
  • RV-1729
    Cat. No.
    A79871

    RV-1729

    RV-1729 is a potent inhibitor of phosphatidylinositol 3-kinase-delta (PI3Kδ), with an IC50 value of 12 nM for the release of phosphatidylinositol 3,4,5-triphosphate (PIP3). This compound exhibits significant selectivity, being twice as selective for PI3Kδ compared to PI3Kγ and 16 times more selective for PI3Kα. RV-1729 modulates immune and inflammatory responses, making it a valuable tool in research applications related to asthma and chronic obstructive pulmonary disease (COPD).

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • PI3K/PIKK-IN-2
    Cat. No.
    A79872

    PI3K/PIKK-IN-2

    PI3K/PIKK-IN-2 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) and phosphoinositide-dependent kinase (PIKK) pathways. This compound demonstrates significant biological activity by modulating signaling pathways involved in cell growth, metabolism, and survival. PI3K/PIKK-IN-2 is suitable for use in research applications focused on targeted therapies, including the development of antibody-drug conjugates (ADCs).

    Out of stock

    All 3 sizes
  • Nemiralisib succinate
    Cat. No.
    A79873

    Nemiralisib succinate

    Synonyms: GSK2269557 succinate

    Nemiralisib succinate is a potent and selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), exhibiting a pKi of 9.9. This compound demonstrates significant anti-inflammatory effects and is utilized in research applications focusing on immune response modulation and cancer therapy. Its specificity for PI3Kδ makes it an important tool for investigating pathways involved in various diseases, particularly those associated with hematological malignancies and autoimmune disorders.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kδ-IN-13
    Cat. No.
    A79874

    PI3Kδ-IN-13

    PI3Kδ-IN-13 is a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 of 2.6 nM. This compound demonstrates significant activity in modulating cell proliferation and has potential applications in researching various diseases, including cancer, infections, inflammation, and autoimmune disorders. Its specificity towards PI3Kδ makes it a valuable tool for dissecting the biological pathways involved in these conditions.

    Out of stock

    All 3 sizes
  • PI3K-IN-19 hydrochloride
    Cat. No.
    A79875

    PI3K-IN-19 hydrochloride

    PI3K-IN-19 hydrochloride is a potent inhibitor of phosphatidylinositol-3-kinase (PI3K), targeting the PI3K signaling pathway involved in cellular growth and survival. This compound demonstrates significant biological activity in modulating PI3K-mediated processes, making it valuable for studying cancer and metabolic disorders. Its application extends to research on drug development and mechanistic studies of PI3K-related pathways.

    5 mg
    $795.00
    All 1 sizes
  • PI3Kδ-IN-18
    Cat. No.
    A79876

    PI3Kδ-IN-18

    PI3Kδ-IN-18 is a highly selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 value below 0.1 nM. This compound demonstrates potent inhibitory activity, making it a valuable tool for research applications focused on autoimmune diseases and related signaling pathways. Its ability to modulate PI3Kδ activity allows for the exploration of therapeutic strategies targeting immune cell functionality and inflammation.

    Out of stock

    All 3 sizes
  • Hit20
    Cat. No.
    A79877

    Hit20

    Hit20 is a selective inhibitor of PI3Kα, effectively inhibiting PI3Kα kinase activity and reducing phosphorylation of this target. This compound demonstrates significant biological activity by suppressing proliferation, colony formation, migration, and invasion in colon cancer cells. Hit20 is a valuable tool for investigating the role of PI3Kα in colon cancer research and therapeutic development.

    Out of stock

    All 3 sizes
  • PI3Kα-IN-15
    Cat. No.
    A79878

    PI3Kα-IN-15

    PI3Kα-IN-15 is a highly selective inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) with an IC50 of 0.15 μM. It demonstrates significant anti-proliferative effects against various cancer cell lines, including SKOV-3, T47D, NCI-H1975, NCI-H460, and MCF-7, with IC50 values of 26.6 μM, 7.9 μM, 32.1 μM, 17.7 μM, and 9.4 μM, respectively. PI3Kα-IN-15 is valuable for investigations into cancer biology and potential therapeutic strategies targeting the PI3K pathway.

    Out of stock

    All 3 sizes
  • PI3K-IN-60
    Cat. No.
    A79879

    PI3K-IN-60

    PI3K-IN-60 is a highly selective inhibitor targeting phosphatidylinositol 3-kinase gamma (PI3Kγ). This compound demonstrates significant biological activity in modulating immune responses and exhibits potential applications in the study of autoimmune diseases, such as multiple sclerosis, as well as various cancer types including breast cancer and pancreatic ductal adenocarcinoma.

    1 mg
    $25.00
    5 mg
    $90.00
    All 6 sizes
  • CXJ-2
    Cat. No.
    A79880

    CXJ-2

    CXJ-2 is a cyclic peptide that serves as a potent inhibitor of the PI3K/ERK signaling pathway. It significantly reduces the proliferation and migration of hepatic stellate cells, demonstrating strong antifibrotic properties. This compound is valuable for research in fibrosis and related hepatic disorders, providing insights into cellular processes influenced by the PI3K/ERK pathway.

    Out of stock

    All 3 sizes
  • PI3K-IN-12
    Cat. No.
    A79881

    PI3K-IN-12

    PI3K-IN-12 is a potent inhibitor of phosphoinositide 3-kinase (PI3K) with a primary mechanism of disrupting PI3K signaling pathways. It demonstrates significant biological activity in modulating cell survival and proliferation, making it a valuable tool for cancer research and studies investigating metabolic disorders. Researchers can utilize PI3K-IN-12 to explore the role of PI3K in various cellular processes and therapeutic interventions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes

Items 326-350 of 369

Added to your cart

View Cart Checkout

    Loading...